Overview Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers Status: Recruiting Trial end date: 2025-12-01 Target enrollment: Participant gender: Summary This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB2922 for injection in subjects with advanced cancers Phase: Phase 1 Details Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.